Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc. BCRX

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedem...


Recent & Breaking News (NDAQ:BCRX)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 16 hours ago

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

GlobeNewswire 3 days ago

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

GlobeNewswire 11 days ago

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

GlobeNewswire January 23, 2023

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

GlobeNewswire January 9, 2023

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

GlobeNewswire January 9, 2023

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 5, 2023

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

GlobeNewswire December 15, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 5, 2022

BioCryst to Present at JMP Securities Hematology & Oncology Summit

GlobeNewswire December 5, 2022

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

GlobeNewswire November 28, 2022

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

GlobeNewswire November 10, 2022

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2022

BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

GlobeNewswire November 1, 2022

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

GlobeNewswire October 24, 2022

BioCryst to Report Third Quarter 2022 Financial Results on November 1

GlobeNewswire October 18, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 4, 2022

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

GlobeNewswire September 14, 2022